3 results match your criteria: "Newcastle upon Tyne Hospitals National Health System Foundation Trust[Affiliation]"
Ibrutinib as part of risk-stratified treatment for posttransplant lymphoproliferative disorder: the phase 2 TIDaL trial.
Blood
July 2024
Northern Centre for Cancer Care, Freeman Hospital, Newcastle upon Tyne Hospitals National Health System Foundation Trust, Newcastle upon Tyne, United Kingdom.
Article Synopsis
- Posttransplant lymphoproliferative disorder (PTLD) is a rare but serious complication in solid organ transplant patients, and chemotherapy can lead to significant side effects.
- The TIDaL trial tested the safety and effectiveness of ibrutinib, alongside a risk-based treatment strategy, for newly diagnosed patients with CD20+ B-cell PTLD.
- While ibrutinib did not meet the effectiveness threshold anticipated, the study highlighted the potential to reduce exposure to harsher chemotherapy treatments for patients in the low-risk category, indicating a direction for future research.
Tossing and Turning in Bed: Nocturnal Movements in Parkinson's Disease.
Mov Disord
June 2020
Laboratory for Early Markers of Neurodegeneration, Center for the Study of Movement, Cognition and Mobility, Neurological Institute, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
Background: Sleep disturbances and nocturnal hypokinesia are common in Parkinson's disease (PD). Recent work using wearable technologies showed fewer nocturnal movements in PD when compared with controls. However, it is unclear how these manifest across the disease spectrum.
View Article and Find Full Text PDFDawn of Epitranscriptomic Medicine.
Circ Genom Precis Med
September 2018
Institute of Cardiovascular Regeneration, Center of Molecular Medicine, Goethe University Frankfurt, Frankfurt am Main, Germany (A.G., K.S.).
Medicine is at the crossroads of expanding disciplines. Prompt adaptation of medicine to each rapidly advancing research field, bridging bench to bedside, is a key step toward health improvement. Cardiovascular disease still ranks first among the mortality causes in the Western world, indicating a poor adaptation rate of cardiovascular medicine, albeit the gigantic scientific breakthroughs of this century.
View Article and Find Full Text PDF